Heron Therapeutics | HRTX - Ebit


Heron Therapeutics reported $38K in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
ALKERMES USD -65.93M 17.65M Jun/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amarin USD -2.26M 564K Dec/2025
ANI Pharmaceuticals USD 39.84M 1.13M Jun/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -154.34M 13.08M Jun/2026
Eisai JPY 24.73B 35.04B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -101.31M 98.97M Jun/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
Merck USD 840M 2.72B Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Omeros USD -48.15M 7.25M Sep/2023
Pacira USD 9.96M 5.33M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Veracyte USD 23.96M 4.88M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026